Examkin

Question

Difficulty: HardEnd-of-Life and Palliative Care

A 74-year-old man with end-stage chronic obstructive pulmonary disease (COPD) is enrolled in home hospice care. He is currently utilizing his continuous home oxygen therapy and maximum tolerated inhaled bronchodilators. Over the ensuing weeks, he begins to experience distressing, progressive episodes of dyspnea at rest. Arrange the following interventions in the most appropriate stepwise sequence for managing his terminal dyspnea, starting from the most appropriate initial next step to the final intervention of last resort.

  1. 1Implement non-pharmacologic measures, such as positioning a fan to blow cool air across the patient's face.
  2. 2Initiate a low-dose, short-acting systemic opioid (e.g., oral morphine).
  3. 3Add an anxiolytic agent (e.g., lorazepam) for severe, concurrent anxiety exacerbating the breathlessness.
  4. 4Initiate palliative sedation therapy with a continuous intravenous infusion (e.g., midazolam).

Answer

The correct sequence begins with non-pharmacologic measures (fan therapy), followed by first-line pharmacologic therapy (systemic opioids), then adjuvant therapy for specific symptom clusters (benzodiazepines for anxiety), and finally, the intervention of last resort (palliative sedation).
In the management of terminal dyspnea, therapy should be escalated in a stepwise fashion based on risk and efficacy. Non-pharmacologic measures (like a fan) are extremely low-risk and often effective. When pharmacologic intervention is required, systemic opioids (like morphine) are the gold-standard first-line agents, as they centrally relieve the sensation of breathlessness. If the patient develops concurrent severe anxiety or panic that exacerbates the dyspnea, benzodiazepines are added as adjuvants. Finally, if the dyspnea becomes entirely refractory to these measures and causes unendurable suffering in the dying patient, palliative sedation (e.g., continuous midazolam) is utilized as the absolute last resort to ensure comfort.

Step-by-Step Solution

1
Identify the initial, lowest-risk intervention for terminal dyspnea.
Non-pharmacologic measures such as a fan directed at the face.
Cool air on the face stimulates trigeminal nerve receptors, providing immediate subjective relief with zero risk of adverse pharmacologic effects, making it the ideal first step.
2
Determine the first-line pharmacologic agent for dyspnea unresponsive to non-pharmacologic measures.
Low-dose, short-acting systemic opioids (e.g., oral morphine).
Opioids are the cornerstone of pharmacologic dyspnea management in terminal illness, effectively reducing ventilatory drive and the perception of breathlessness without significantly compromising gas exchange when dosed carefully.
3
Identify the role of adjuvant medications.
Addition of a benzodiazepine (e.g., lorazepam).
Benzodiazepines are not indicated for dyspnea itself but are the appropriate next step when dyspnea is compounded by severe anxiety or panic that is refractory to the reassurance provided by opioids.
4
Determine the final intervention for truly intractable symptoms.
Palliative sedation.
When all other measures fail to relieve suffering in a terminally ill patient, proportionate palliative sedation to unconsciousness is the ethical and clinical last resort.

Key Concept

The stepwise management of terminal dyspnea prioritizes low-risk non-pharmacologic interventions, followed by systemic opioids as the primary pharmacologic treatment, adjuvants like benzodiazepines for concurrent anxiety, and reserves palliative sedation as a final resort for intractable suffering.
Estimated Time:1m 30s
Rate this question

Topics

End-of-Life and Palliative Care

More questions from this topic